Researchers from Tulane University and Shenzhen Third People’s Hospital have developed ActCRISPR-TB, an enhanced CRISPR-Cas12a assay for tuberculosis detection from non-sputum samples like cheek swabs and stool. The single-tube, one-pot assay delivers results in under an hour and does not require cold storage, ideal for resource-limited settings. With sensitivity surpassing traditional sputum tests, ActCRISPR-TB aims to enable widespread community screening to curtail undiagnosed cases and improve TB control in high-burden areas.